APPROVED
by order of chairman of Committee of medicinal and pharmaceutical activities of Ministry of Healthcare of Republic of Kazakhstan
“__”_____201_____
N_____

INSTRUCTION for medical use of medicinal product BRONCHOSTOP® Pastilles

Trade name
Bronchostop® Pastilles

International nonproprietary name
No

Dosage form
Pastilles

Composition
One pastille (2 g) contains
active ingredient: thyme herb dry extract 59.5 mg,
excipients: maltodextrin, acacia, fructose, sorbitol solution 70% non crystallizing (E 420), citric acid anhydrous, sodium saccharin (E 954), chokeberry flavoring, berry flavoring, paraffin liquid, paraffin liquid, purified water.

During manufacturing process of thyme herb dry extract (ratio of raw material to extraction solvent 7 – 13 : 1) water was used like extraction solvent.

Appearance
Pastilles of hexagonal shape, brown colour with fruity taste.

Pharmacotherapeutic group
Cough and cold preparations.
Expectorants.
ATC code R05C A

Pharmacological properties
Pharmacokinetics
Not required.
Pharmacodynamics
Extract of thyme has secretolytic, expectorative and broncholytic properties and supports the expectoration of viscous mucus. The essential oil, which is contained in the thyme herb extract, has antiseptic properties.

Indications.
- an expectorant in cough associated with cold of upper air passages.

Method of administration and doses
For oral use.
Adults and adolescents over 12:
When necessary 1-2 pastilles must be consecutively dissolved each 3-4 hours per day (4-6 times per day).
Children between 6 - 12:
When necessary 1pastille must be dissolved each 3-4 times per day (4-6 times per day).
If in 7 days no improvement has occurred it is necessary to consults a doctor.

Undesirable effects
- hypersensitivity reactions (including one case of anaphylactic shock and one case of Quincke's oedema)
- stomach disorders.
The frequency is not known.

Contraindications
- hypersensitivity to the active substances, to other members of the Lamiaceae family or to any of the excipients
- hereditary intolerance of fructose, malabsorption of glucose and galactose
- pregnancy and lactation
- children with age under 6 years.

Interaction with medicinal products
No interaction studies have been performed.

Special warnings
Due to lack of data and because of the risk of unintentionally swallowing the entire pastille, the use in children under 6 years of age is not recommended.
Products contain fructose, sorbitol, saccharine. Patients who suffer from the rare hereditary fructose intolerance should not apply Bronchostop Pastilles.
In case of deterioration the development of breathing, temperature rise or the appearance of purulent sputum, you need to see a doctor.
Pregnancy and lactation.
In the absence of sufficient data, the use during pregnancy and lactation is not recommended.
Effects on ability to drive and to use machines.
No studies on the effects on the ability to drive and use machines have been performed.

Overdose
No case of overdose has been reported.

Package and presentation
10 pastilles hermetically packed in contour-cellular package from PVC/PE/PVDC and aluminum foil.
2 contour packages with instruction for medical use in state and Russian languages in the carton box.

Storage conditions
Do not store above 25°C in place protected from light.
Keep out of reach of children!

Shelf life
3 years
Do not use the medicine after expiry date.

Release category
Without prescription

Manufacturer
Bolder Arzneimittel GmbH & Co. KG
Rheinische Allee 11, 50858 Koln, Germany.

Manufacturing authorization holder
Kwizda Pharma GmbH,
Effingergasse 21, 1160 Vienna, Austria.

Address of the entity receiving the complaints from consumers on the quality of products (goods) on the territory of the Republic of Kazakhstan:
Representative office of Delta Medical Promotions AG (Switzerland)
050040, Almaty, Bostandyk district, st. Baizakov, d.280
Tel. / fax: +7 (727) 332 20 79
E-mail: PVG@deltamedical.com.ua